Literature DB >> 15879620

Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Thomas Pusl1, Ulrich Beuers.   

Abstract

Pruritus, fatigue, and metabolic bone disease are frequent complications of cholestatic liver diseases, which can be quite distressing for the patient and can considerably reduce the quality of life. The molecular pathogenesis of these extrahepatic manifestations of cholestasis is poorly understood, and hypotheses to explain these symptoms are being discussed. This article provides treatment recommendations for the complications of cholestasis based on putative pathomechanisms and summarizes recent experimental and clinical data involving management options.

Entities:  

Mesh:

Year:  2005        PMID: 15879620     DOI: 10.1385/CRIAI:28:2:147

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  162 in total

Review 1.  Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis.

Authors:  E A Jones; N V Bergasa
Journal:  Can J Gastroenterol       Date:  2000-01       Impact factor: 3.522

Review 2.  The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

Authors:  L C Hofbauer; S Khosla; C R Dunstan; D L Lacey; W J Boyle; B L Riggs
Journal:  J Bone Miner Res       Date:  2000-01       Impact factor: 6.741

3.  Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis.

Authors:  E A Jones; L R Dekker
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

4.  Association of primary biliary cirrhosis with vitamin D receptor BsmI genotype polymorphism in a Hungarian population.

Authors:  B Halmos; F Szalay; T Cserniczky; E Nemesanszky; P Lakatos; S Barlage; G Schmitz; L Romics; A Csaszar
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

5.  Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis.

Authors:  J Goulis; G Leandro; A K Burroughs
Journal:  Lancet       Date:  1999-09-25       Impact factor: 79.321

6.  Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use.

Authors:  M I Prince; O F James; N P Holland; D E Jones
Journal:  J Hepatol       Date:  2000-03       Impact factor: 25.083

7.  Defective corticotropin-releasing hormone mediated neuroendocrine and behavioral responses in cholestatic rats: implications for cholestatic liver disease-related sickness behaviors.

Authors:  M G Swain; M Maric
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

8.  Treatment of pruritus of primary biliary cirrhosis with rifampin.

Authors:  A Podesta; P Lopez; R Terg; F Villamil; D Flores; R Mastai; C B Udaondo; J P Companc
Journal:  Dig Dis Sci       Date:  1991-02       Impact factor: 3.199

Review 9.  Primary biliary cirrhosis: new therapeutic directions.

Authors:  C L Berg; J L Gollan
Journal:  Scand J Gastroenterol Suppl       Date:  1992

10.  Induction of hepatic microsomal enzymes after brief administration of rifampicin in man.

Authors:  J P Miguet; P Mavier; C J Soussy; D Dhumeaux
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

View more
  9 in total

Review 1.  Hepatic osteodystrophy.

Authors:  Angelo Gatta; Alberto Verardo; Marco Di Pascoli; Sandro Giannini; Massimo Bolognesi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

Review 2.  Use and indications of cholestyramine and bile acid sequestrants.

Authors:  Franco Scaldaferri; Marco Pizzoferrato; Francesca Romana Ponziani; Giovanni Gasbarrini; Antonio Gasbarrini
Journal:  Intern Emerg Med       Date:  2011-07-08       Impact factor: 3.397

3.  Hepatic osteodystrophy: An important matter for consideration in chronic liver disease.

Authors:  Germán López-Larramona; Alfredo J Lucendo; Sonia González-Castillo; José M Tenias
Journal:  World J Hepatol       Date:  2011-12-27

4.  Modeling hepatic osteodystrophy in Abcb4 deficient mice.

Authors:  Katrin Hochrath; Sabrina Ehnert; Cheryl L Ackert-Bicknell; Yvonne Lau; Andrea Schmid; Marcin Krawczyk; Jan G Hengstler; Jordanne Dunn; Kanishka Hiththetiya; Birgit Rathkolb; Kateryna Micklich; Wolfgang Hans; Helmut Fuchs; Valérie Gailus-Durner; Eckhard Wolf; Martin Hrabě de Angelis; Steven Dooley; Beverly Paigen; Britt Wildemann; Frank Lammert; Andreas K Nüssler
Journal:  Bone       Date:  2013-03-29       Impact factor: 4.398

5.  Cholestatic pruritus: Emerging mechanisms and therapeutics.

Authors:  Sagar P Patel; Chirag Vasavda; Byron Ho; James Meixiong; Xinzhong Dong; Shawn G Kwatra
Journal:  J Am Acad Dermatol       Date:  2019-04-19       Impact factor: 11.527

Review 6.  Cholestasis and metabolic bone disease - a clinical review.

Authors:  Rudolf W Gasser
Journal:  Wien Med Wochenschr       Date:  2008

Review 7.  Pathogenesis and treatment of pruritus in cholestasis.

Authors:  Andreas E Kremer; Ulrich Beuers; Ronald P J Oude-Elferink; Thomas Pusl
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Low bone mineral density and the severity of cholestasis in biliary atresia.

Authors:  Krittapak Homchan; Tawatchai Chaiwatanarat; Wanvisa Udomsinprasert; Voranush Chongsrisawat; Yong Poovorawan; Sittisak Honsawek
Journal:  World J Hepatol       Date:  2017-06-08

9.  Reduced spontaneous itch in mouse models of cholestasis.

Authors:  Jacqueline Langedijk; Ruth Bolier; Dagmar Tolenaars; Lysbeth Ten Bloemendaal; Suzanne Duijst; Dirk de Waart; Ulrich Beuers; Piter Bosma; Ronald Oude Elferink
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.